http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-109735546-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-861 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-113 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-713 |
| filingDate | 2019-02-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2021-04-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2021-04-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-109735546-B |
| titleOfInvention | siRNA for inhibiting BNIP3L protein expression and application thereof in preparing anti-vascular fibrosis drugs |
| abstract | The invention discloses siRNA for inhibiting BNIP3L protein expression and application thereof in preparing anti-vascular fibrosis drugs, wherein the siRNA for inhibiting BNIP3L protein expression consists of a sense strand and an antisense strand, the nucleotide sequence of the sense strand is shown by SEQ ID No.1, and the nucleotide sequence of the antisense strand is shown by SEQ ID No. 2. The siRNA for inhibiting the expression of the BNIP3L protein can obviously and specifically inhibit the expression of BNIP3L in vascular smooth muscle cells, obviously inhibit the cell cycle process of the vascular smooth muscle cells after transfection of siRNA adenovirus, obviously inhibit the proliferation of the vascular smooth muscle cells, and obviously inhibit the expression of extracellular matrix protein, thereby playing a role in preventing pathological vascular fibrosis. |
| priorityDate | 2019-02-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 187.